Skip to search formSkip to main contentSkip to account menu

LY2606368

National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

PrexasertibPyrazinesPyrazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract CT232: Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumors
Background: Checkpoint kinase 1 (CHK1) plays a central role in replication fork stabilization and homologous recombination repair… 
2019
2019
Abstract 1761: Inhibition of PI3K/AKT/mTOR signaling by a dual PI3K/mTOR inhibitor (LY3023414) potentiates the antitumor efficacy of the Chk1 inhibitor prexasertib (LY2606368) in models of human high…
HGSOC (characterized by defects in DNA damage repair and high levels of genomic instability and DNA replication stress) is the… 
2018
2018
Chk-mate on resistance to kinase inhibitors
The invariable development of drug resistance represents a major obstacle to the successful treatment of cancer with kinase… 
2017
2017
Chk 1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN 673 in gastric cancer
Globally, gastric cancer is the second leading cause of cancer deaths because of the lack of effective treatments for patients… 
2017
2017
Chemotherapy, “Lighting the Fire” or “Releasing the Brakes” in Metastatic Anal Cancer
Squamous cell carcinoma of the anus (SCCA) is a rare cancer. Few patients have overt metastatic disease at presentation, and only… 
2016
2016
Abstract 2723: The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia
Different Checkpoint kinase inhibitors (Chk-i) have been developed to increase the cytotoxic effect of genotoxic agents… 
2015
2015
Causes Replication Catastrophe and Antitumor Effects through CHK 1-Dependent Mechanisms
CHK1 is a multifunctional protein kinase integral to both the cellular response to DNA damage and control of the number of active… 
2015
2015
Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus.
3520 Background: LY2606368 is a CHK 1/2 inhibitor. CHK1 is a multifunctional kinase essential for checkpoint control, DNA repair… 
2013
2013
Abstract LB-200: Dose and schedule determination of the Chk1/2 inhibitor LY2606368 in patients with solid tumors.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background: LY2606368 mesylate hydrate (LY2606368… 
2012
2012
Abstract 1776: Antitumor activity of Chk1 inhibitor LY2606368 as a single agent in SW1990 human pancreas orthotopic tumor model
ChK1 is a key kinase in the DNA damage response signaling network, including cell cycle checkpoints, DNA repair, apoptosis and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)